Amgen discontinued its early-stage obesity candidate AMG-513, leaving the company to reallocate resources and increase pressure on late-stage competitors. The company did not provide detailed reasons for halting the program, but the move signals a portfolio shift as obesity development remains highly competitive across GLP-1 and next-generation modalities.